JPMorgan says Lilly data ‘highly favorable' for Structure Therapeutics
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on GPCR:
Disclaimer & DisclosureReport an Issue
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill
JPMorgan says Pfizer news 'mostly a positive' for Structure, Viking
Viking, Structure rally after Pfizer halts obesity drug development
Pfizer Stock (PFE) Dips after Weight-Loss Pill Halted Over Liver Injury
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
JPMorgan Chase appoints David Frame as global private bank CEO
JPMorgan Chase has appointed David Frame as the global CEO of its private bank, effective immediately. This move positions Frame, previously the US private bank CEO, to lead the bank's private banking operations on a global scale, reported Reuters. The private bank, part of JPMorgan's asset and wealth management division, caters to high-net-worth clients. The private banking sector has gained prominence as global lenders aim to strengthen ties with wealthy clients and access the expanding global wealth pool. In addition to investment management, private banks provide services like lending, estate planning, and philanthropy, contributing to stable fee income and diversifying revenue streams away from Wall Street's volatility, reported the media outlet. With over $2.9tn in client assets under management, JPMorgan's private banking business is a significant player in the industry. As geopolitical tensions and economic uncertainties rise, wealthy investors increasingly seek global private banks for cross-border investment advice and access to private markets. Frame will continue to report to J.P. Morgan Asset and Wealth Management CEO Mary Callahan Erdoes, who oversees more than $6tn in assets. In May, JPMorgan Chase opened 14 new financial centres in the four US states of California, Florida, Massachusetts, and New York. The expansion follows the establishment of two additional centres in late 2024, bringing the total to 16, with plans to nearly double this number by the end of next year. "JPMorgan Chase appoints David Frame as global private bank CEO" was originally created and published by Private Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
How to Play Morgan Stanley Stock as Global M&As Rebound?
While market uncertainties, driven by President Donald Trump's trade war, elevated interest rates and broader geopolitical tensions posed challenges, they did not fully spoil what many bankers had anticipated would be a blockbuster year for global dealmaking. The year began on an optimistic note, but market sentiment cooled after Trump's tariff policies launched on 'Liberation Day', casting a shadow over dealmaking. Yet, momentum has since rebounded, with activity picking up in recent months. This seems to be the right time to keep an eye on Morgan Stanley MS stock before it of MS, one of the most well-known global investment banks, have risen just 14.6% this year. In contrast, the company's peers, Goldman Sachs GS and JPMorgan JPM, have fared much better, with their stocks gaining 26.4% and 23.5%, respectively. YTD Price Performance Image Source: Zacks Investment Research The data available from Dealogic shows that despite an initial hiccup, the appetite for mergers and acquisitions (M&As) remains resilient in the face of market volatility, geopolitical tension and Trump's shifting tariff landscape. Many deals that were put on hold are likely to come back once there is more certainty about the direction of the economy, as capital remains available. This will act as a tailwind for investment banks such as Morgan Stanley, JPMorgan and Goldman, which generate billions in revenues from M&A advisory the first quarter of 2025, industry-wide investment banking (IB) business witnessed better-than-expected activity, and Morgan Stanley performed well. The company's total IB fees (in the Institutional Securities division) grew 7.7% year over year to $1.56 billion. MS' second-quarter IB performance is likely to be muted due to the above-mentioned headwinds. The Zacks Consensus Estimate for IB fees (in the Institutional Securities division) is expected to be $1.49 billion, marking a sequential and year-over-year the second-half prospects look encouraging, and Morgan Stanley is likely to record a solid improvement in IB fees. Morgan Stanley has lowered its reliance on capital markets for income generation. The company's focus on expanding its wealth and asset management operations and strategic acquisitions, including Eaton Vance, E*Trade Financial and Shareworks, is a step in that direction. These moves have bolstered its diversification efforts, enhanced stability and created a more balanced revenue stream across market cycles. Both businesses' aggregate contribution to net revenues jumped to more than 55% in 2024 from 26% in 2010. For the first quarter of 2025, the aggregate contribution to net revenues was 50.3%.In the first quarter, Morgan Stanley reported net outflows of $13.6 billion in the Investment Management division owing to volatile markets. On the other hand, assets under management or supervision rose 9.4% year over year to $1.6 trillion as of March 31, 2025. Further, the Wealth Management division's total client assets increased 9.5% on a year-over-year basis to $6 billion. Morgan Stanley's partnership with Mitsubishi UFJ Financial Group, Inc. MUFG is expected to continue supporting its financials. In 2023, the companies announced plans to deepen their 15-year alliance by merging certain operations within their Japanese brokerage joint new strategic alliance involves combined Japanese equity research, sales and execution services for institutional clients at Mitsubishi UFJ Morgan Stanley Securities and Morgan Stanley MUFG Securities. Also, their equity underwriting business has been rearranged between the two brokerage units. These efforts will solidify the company's position in the lucrative Japanese helped MS achieve record equity net revenues in the first quarter of 2025, particularly in Asia, through outperformance in prime brokerage and derivatives driven by solid client activity amid heightened volatility. Further, the company's Asia region revenues jumped 34.5% year over year to $2.35 billion during the quarter. As of March 31, 2025, Morgan Stanley had a long-term debt of $297 billion, with only approximately $23 billion expected to mature over the next 12 months. The company's average liquidity resources were $351.7 billion as of the same date. Moreover, the company enjoys investment-grade long-term credit ratings of A1, A- and A+ from Moody's, S&P Global Ratings and Fitch Ratings, respectively, and a stable outlook allows easy access to the debt market. Thus, a solid balance sheet position supports its enhanced capital clearing the 2025 stress test, Morgan Stanley announced plans to increase its quarterly dividend by 8% to $1 per share. Also, the company has reauthorized its share repurchase program of up to $20 billion. Over the past five years, the company has raised its dividends four times, with an annualized growth rate of 25.2%. Over the past month, the Zacks Consensus Estimate for 2025 and 2026 earnings has been revised marginally lower to $8.54 and $9.26, respectively. Estimate Revision Trend Image Source: Zacks Investment Research The Zacks Consensus Estimate for Morgan Stanley's 2025 and 2026 earnings implies year-over-year growth of 7.4% and 8.4%, respectively. From a valuation perspective, MS stock is currently trading at a forward 12-month price/earnings (P/E) of 16.19X. This is above the industry's 14.96X. Price-to-Earnings F12M Image Source: Zacks Investment Research On the other hand, JPMorgan and Goldman Sachs have a forward P/E of 15.54X and 15.31X, respectively. This reflects that Morgan Stanley is expensive compared to its Stanley's strong global presence and strategic focus on stable revenue streams provide a solid foundation for organic growth. Its diversified business model ensures resilience and growth potential, even in volatile market conditions. Resilient M&A pipelines and solid trading revenues are other the company has been witnessing a rise in expenses. Though expenses declined in 2022, the metric recorded a five-year (ending 2024) CAGR of 7.8%, with the uptrend continuing in the first quarter of 2025. Expenses are likely to remain elevated, given higher compensation costs, inflationary pressure and inorganic growth the current trend points toward a resurgence in global M&As, investors must keep a watch on the trends and macroeconomic developments before taking any investment decision. Also, the stock's premium valuation and bearish analyst sentiment warrant careful consideration. Hence, MS stock is a cautious Stanley currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Morgan Stanley (MS) : Free Stock Analysis Report Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
20 hours ago
- Yahoo
2 Stocks to Buy With Less Than $50
Pfizer is slowly building a foundation that will help its business recover from recent headwinds. Encouraging developments on the clinical front should boost shares of cancer specialist Exelixis. 10 stocks we like better than Pfizer › One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices. Here are two excellent examples in the healthcare industry: Pfizer (NYSE: PFE) and Exelixis (NASDAQ: EXEL). These drugmakers are worth investing in, and both are changing hands for under $50 apiece. Here is what investors need to know. Pfizer's shares have declined significantly over the past few years as its revenue and earnings dipped following its coronavirus-related success. What's more, the company could face more trouble soon. The drugmaker will encounter significant patent cliffs in the next few years, particularly for Eliquis, an anticoagulant. However, at about $25 per share, Pfizer looks attractive. Here are four reasons why. First, the company should succeed in rejuvenating its lineup. Pfizer has improved its pipeline over the past few years. It has also earned major approvals. Though they are not yet helping the company's revenue move in the right direction consistently, that will happen in time. Second, Pfizer has been engaged in cost-cutting efforts to help boost its bottom line. Pfizer is still at it and is planning to reduce expenses even more through 2027. Third, Pfizer offers a terrific dividend program. The company has increased its payouts by 19.45% in the past five years. Pfizer's forward yield is 7.1% -- that's well above the S&P 500's average of 1.3%. Pfizer should continue to reward loyal shareholders in this manner. Lastly, the stock appears to be more than reasonably valued. Pfizer's forward price-to-earnings ratio comes in at a dirt-cheap 8.3, well below the average of 16.1 for the healthcare industry. Pfizer's stock might not recover overnight. However, for patient, income-seeking investors, it is worth investing in the company right now. Over time, that investment could pay for itself. Exelixis is a relatively small drugmaker that specializes in oncology. The company's top-selling product is Cabometyx, which is approved to treat several kinds of cancers, most notably some forms of liver and kidney cancer. Cabometyx has been a hit and has helped Exelixis' revenue and earnings move in the right direction for years. However, the biotech company has become even more attractive over the past 18 months. Here are three things that happened. First, Exelixis won a patent litigation case that will help keep a Cabometyx generic off the market until early 2030. Had the drugmaker lost this lawsuit, it might have been disastrous for its financial results. Second, Cabometyx won another label expansion, this time for the treatment of pancreatic neuroendocrine tumors. Cabometyx has maintained an upward sales trajectory by holding a leading market share for medicines of its type among patients with renal cell carcinoma (kidney cancer), and thanks to label expansions. If it's not broken, don't fix it. Third, Exelixis recently announced positive top-line results for its next-gen cancer medicine, zanzalintinib, in a phase 3 study that enrolled patients with metastatic colorectal cancer. Although colorectal cancer is highly treatable when caught early, as Exelixis points out, five-year survival rates drop once it has metastasized, meaning there is an unmet need in that niche. The biotech's zanzalintinib could help fill that need and help decrease the company's exposure to Cabometyx, all in one fell swoop. With all that going on, the future looks brighter than ever for Exelixis. Shares are changing hands for $44 apiece. Investing in the stock and holding on to it for five years or more could lead to solid returns. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Exelixis. The Motley Fool has positions in and recommends Exelixis and Pfizer. The Motley Fool has a disclosure policy. 2 Stocks to Buy With Less Than $50 was originally published by The Motley Fool Sign in to access your portfolio
